Publications by authors named "Per T Pedersen"

Claim this Profile
T
Thrombotic Thrombocytopenic Purpura and Evans Syndrome: Validating and Exploring 20 Years of Routine Hospital Care.
Dana Audrey Lawrie, Dennis Lund Hansen, Thomas Leineweber Kristensen, Sarah Birgitte Ingemod Sand Carlsen, Louise Hur Hannig, Per Trøllund Pedersen, Robert Schou Pedersen

J Blood Med· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship between reasons for intermittent missing patient-reported outcomes data and missing data mechanisms.
Lene Kongsgaard Nielsen, Rebecca Mercieca-Bebber, Sören Möller, Louise Redder, Mary Jarden, Per Trøllund Pedersen

Qual Life Res· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nationwide implementation of lenalidomide maintenance in multiple myeloma: A retrospective, real-world study.
Mads Harsløf, Iman Chanchiri, Trine Silkjær, Ulf Christian Frølund, Elena Manuela Teodorescu, Per Trøllund Pedersen

EJHaem· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world outcomes following third or subsequent lines of therapy: A Danish population-based study on 189 patients with relapsed/refractory large B-cell lymphomas.
Ahmed Ludvigsen Al-Mashhadi, Lasse Hjort Jakobsen, Peter Brown, Anne Ortved Gang, Anne-Luise Thorsteinsson, Per Trøllund Pedersen

Br J Haematol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Geographical and ecological analyses of multiple myeloma in Denmark: Identification of potential hotspot areas and impact of urbanisation.
Lise Dueholm Bertelsen, Lars Børty Nielsen, Heidi Søgaard Christensen, Martin Bøgsted, Henrik Gregersen, Robert Schou Pedersen, Per Trøllund Pedersen

Eur J Haematol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patients in complete remission after R-CHOP(-like) therapy for diffuse large B-cell lymphoma have limited excess use of health care services in Denmark.
Lasse Hjort Jakobsen, Andreas Kiesbye Øvlisen, Marianne Tang Severinsen, Joachim Bæch, Kristian Hay Kragholm, Per Trøllund Pedersen, Robert Schou Pedersen, Christian Torp-Pedersen

Blood Cancer J· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation; a population-based study from the Danish national multiple myeloma registry.
Louise Redder, Tobias W Klausen, Annette Juul Vangsted, Henrik Gregersen, Niels F Andersen, Robert S Pedersen, Per T Pedersen

Br J Haematol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence and clinical characteristics of multiple myeloma with low M-protein levels and normal values of hemoglobin, creatinine, calcium, and serum free light chain ratio.
Agoston Gyula Szabo, Tobias Wirenfeldt Klausen, Niels Abildgaard, Henrik Gregersen, Trine Silkjær, Per Trøllund Pedersen, Robert Schou Pedersen

Blood Cancer J· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic significance of infectious episodes occurring during first-line therapy for diffuse large B-cell lymphoma - A nationwide cohort study.
Michael R Clausen, Sinna P Ulrichsen, Maja B Juul, Christian B Poulsen, Brian Iversen, Per T Pedersen, Robert S Pedersen

Hematol Oncol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Strategies to improve patient-reported outcome completion rates in longitudinal studies.
Lene Kongsgaard Nielsen, Madeleine King, Sören Möller, Mary Jarden, Christen Lykkegaard Andersen, Per Trøllund Pedersen

Qual Life Res· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No differential overall or relative survival effect of rituximab in male and female patients with diffuse large B-cell lymphoma: a Danish population-based study of 3783 patients.
Lasse Hjort Jakobsen, Jorne Lionel Biccler, Peter de Nully Brown, Judit Mészáros Jørgensen, Pär Lars Josefsson, Per Trøllund Pedersen

Leuk Lymphoma· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pretreatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing Chemotherapy.
Michael R Clausen, Matthew J Maurer, Sinna Pilgaard Ulrichsen, Thomas S Larsen, Bodil Himmelstrup, Per Trøllund Pedersen, Robert S Pedersen

Clin Epidemiol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Depth of neutrophil nadir after first cycle of R-CHOP predicts outcome in diffuse large B-cell lymphoma - a nationwide population-based cohort study.
Michael Roost Clausen, Sinna Pilgaard Ulrichsen, Thomas Stauffer Larsen, Christian B Poulsen, Selma Tojaga, Per Trøllund Pedersen, Robert Schou Pedersen

Leuk Lymphoma· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Eosinophilia].
Ole Weis Bjerrum, Daniel El Fassi, Gitte Madsen, Jesper Stentoft, Hanne Vestergaard, Per Trøllund Pedersen

Ugeskr Laeger· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population.
Rasmus Sørrig, Tobias W Klausen, Morten Salomo, Annette J Vangsted, Ulf Christian Frølund, Robert S Pedersen, Per T Pedersen

PLoS One· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based study.
Henrik Gregersen, Annette Juul Vangsted, Niels Abildgaard, Niels Frost Andersen, Robert Schou Pedersen, Per Trøllund Pedersen

Cancer Med· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Danish National Acute Leukemia Registry.
Lene Sofie Granfeldt Østgård, Jan Maxwell Nørgaard, Klas Kræsten Raaschou-Jensen, Robert Schou Pedersen, Dorthe Rønnov-Jessen, Per Troellund Pedersen

Clin Epidemiol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Danish National Multiple Myeloma Registry.
Peter Gimsing, Morten O Holmström, Tobias Wirenfelt Klausen, Niels Frost Andersen, Henrik Gregersen, Robert Schou Pedersen, Per Trøllund Pedersen

Clin Epidemiol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support: A study based on the nationwide Danish Myeloma Database.
Morten O Holmström, Peter Gimsing, Niels Abildgaard, Niels F Andersen, Carsten Helleberg, Per T Pedersen, Robert Schou Pedersen

Am J Hematol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Cutaneous and haematological adverse events after methotrexate therapy].
Ann-Kathrine Rossau, Per Trøllund Pedersen, Anette Bygum

Ugeskr Laeger· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR.
Charlotte T Hansen, Per T Pedersen, Lars C Nielsen, Niels Abildgaard

Eur J Haematol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study.
Martin Hjorth, Øyvind Hjertner, Lene Meldgaard Knudsen, Nina Gulbrandsen, Erik Holmberg, Per Trøllund Pedersen

Eur J Haematol· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro.
Thomas Lund, Kent Søe, Niels Abildgaard, Patrick Garnero, Per T Pedersen

Eur J Haematol· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis